Novel subtype specific and universal somatostatin analogues: Clinical potential and pitfalls

Current Pharmaceutical Design

Volumn 11, Issue 12, 2005, Pages 1573-1592

  van der Hoek, Joost ^a   Hofland, Leo J ^a   Lamberts, Steven W J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Neuroendocrine tumours; Somatostatin (SS); SS analogues; SS receptor subtype (sst)

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ADENOHYPOPHYSIS HORMONE; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; BETA CASOMORPHINE DERIVATIVE; BETA PEPTIDE; BIM 23190; BIM 23197; BIM 23244; BIM 23268; BIM 23454; BIM 23627; BIM 23745; BIM 23926; BIM 23A387; BN 81674; C PEPTIDE; CARBOLINE DERIVATIVE; COPPER 64; CYCLAM; CYCLOPEPTIDE; CYN 154806; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLCYSTEINYLTHREONINAMIDE 2,7 DISULFIDE 2 PYRROLINODOXORUBICIN; DEXTRO PHENYLALANYLPHENYLALANYLPHENYLALANYL DEXTRO TRYPTOPHYLLYSYLTHREONYLPHENYLALANYLTHREONINAMIDE; DEXTRO PHENYLALANYLPHENYLALANYLTYROSYL DEXTRO TRYPTOPHYLLYSYLVALYLPHENYLALANYL DEXTRO [3 (2 NAPHTHYL)ALANINAMIDE]; DOXORUBICIN; GASTROINTESTINAL HORMONE; KE 108; L 363377; L 779976; L 796778; L 797591; L 803087; L 817818; METHOTREXATE; MORPHINE; OCTREOTATE; OCTREOTIDE; PANCREAS HORMONE; PASIREOTIDE; PENTETIC ACID; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE DERIVATIVE; PTR 3173; QUINOLINE DERIVATIVE; RECEPTOR SUBTYPE; SOMATOSTATIN; SOMATOSTATIN 14; SOMATOSTATIN 28; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; SRA 880; TYROSINE; UNCLASSIFIED DRUG; UREA; VAPREOTIDE; YTTRIUM 90;

ABDOMINAL DISCOMFORT; ADENOHYPOPHYSIS; ADRENAL DISEASE; ANEMIA; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG STABILITY; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOCRINE TUMOR; GALLSTONE; GASTROINTESTINAL TRACT; GASTROINTESTINAL TUMOR; GONAD DYSFUNCTION; HORMONE INHIBITION; HUMAN; HYPERGLYCEMIA; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; KIDNEY FAILURE; LYMPHOCYTOPENIA; NAUSEA; NEPHROTOXICITY; NEUROENDOCRINE DISEASE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS; PANCREAS TUMOR; PANCYTOPENIA; PATHOPHYSIOLOGY; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN PURIFICATION; REVIEW; RISK BENEFIT ANALYSIS; TACHYPHYLAXIS; THYROID DISEASE;

ADENOMA; ANIMALS; DRUG RESISTANCE; HUMANS; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN; TACHYPHYLAXIS;

EID: 18944406956     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053764832     Document Type: Review

References (126)

1. Brazeau P, Vale W, Burgus R, Ling N, Butcher M, Rivier J, et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 1973; 179(68): 77-9.
2. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20(3): 157-98.
3. Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. Opportunities in somatostatin research: biological, chemical and therapeutie aspects. Nat Rev Drug Discov 2003; 2(12): 999-1017.
4. Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci 1995; 16(3): 86-8.
5. Reisine T, Bell GI. Molecular biology of somatostatin receptors. Endocr Rev 1995; 16(4): 427-42.
6. Patel YC, Greenwood M, Kent G, Panetta R, Srikant CB. Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 1993; 192(1): 288-94.
7. Vanetti M, Kouba M, Wang X, Vogt G, Hollt V. Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett 1992; 311(3): 290-4.
8. Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sei USA 1992; 89(1): 251-5.
9. Schaer JC, Waser B, Mengod G, Reubi JC. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comprison of mRNA analysis with receptor autoradiography. Int J Cancer 1997: 70(5): 530-7.
10. Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 2003; 1616( 1): 1-84.
11. Lahlou H, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, et al. Molecular signaling of somatostatin receptors. Ann N Y Acad Sci 2004; 1014: 121-31.
12. Benali N, Ferjoux G, Puente E, Buscail L, Susini C. Somatostatin receptors. Digestion 2000; 62(Suppl 1): 27-32.
13. Barnett P. Somatostatin and somatostatin receptor physiology. Endocrine 2003; 20(3): 255-64.
14. Lamberts SW, van der Lely AJ, Hofland LJ. New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol 2002; 146(5): 701-5.
15. Guillermet J, Saint-Laurent N, Rochaix P, Cuvillier O, Levade T, Schally AV, et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc Natl Acad Sei U S A 2003; 100(1): 155-60.
16. Sharma K, Patel YC, Srikant CB. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 1996; 10(12): 1688-96.
17. Teijeiro R, Rios R, Costoya JA, Castro R, Bello JL, Devesa J, et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 2002; 12(1): 31-8.
18. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001; 28(7): 836-46.
19. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, et al. Subtype-selective expression of the five somatostatin receptors (hSSTR1- 5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999; 48(1): 77-85.
20. Hofland LJ, Lamberts SW. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 2003; 24(1): 28-47.
21. Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334(4): 246-54.
22. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12(4): 450-82.
23. Schonbruon A. Somatostatin receptors present knowledge and future directions. Ann Oncol 1999; 10 Suppl 2: S17-21.
24. Csaba Z, Dournaud P. Cellular biology of somatostatin receptors. Neuropeptides 2001; 35(1): 1-23.
25. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sei 1995; 57(13): 1249-65.
26. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996; 137(9): 4046-9.
27. Rocheville M, Lange DC, Kumar U, Sasi R, Patel RC, Patel YC. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J Biol Chem 2000; 275(11): 7862-9.
28. Hukovic N, Rocheville M, Kumar U, Sasi R, Khare S, Patel YC. Agonist-dependent up-regulation of human somatostatin receptor type l requires molecular signals in the cytoplasmic C-tail. J Biol Chem 1999; 274(35): 24550-8.
29. Stroh T, Jackson AC, Sarret P, Dal Farra C, Vincent JP, Kreienkamp HJ, et al. Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. Endocrinology 2000; 141(1): 354-65.
30. Pfeiffer M, Koch T, Schroder H, Klutzny M, Kirscht S, Kreienkamp HJ, et al. Homo- and heterodimerization of somatostatin receptor subtypes. Inactivation of sst(3) receptor function by heterodimerization with sst(2A). J Biol Chem 2001; 276(17): 14027-36.
31. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002; 277(22): 19762-72.
32. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000; 288(5463): 154-7.
33. George SR, O'Dowd BF, Lee SP. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1(10): 808-20.
34. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003; 30(5): 781-93.
35. Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87(7): 3013-8.
36. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J Clin Invest 1997; 99(4): 789-98.
37. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD, Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J Clin Invest 1997; 100(9): 2386-92.
38. Shimon I. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs. Endocrine 2003; 20(3): 265-70.
39. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, et al. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002; 297(4): 828-34.
40. Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab 2003; 88(6): 2797-802.
41. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Dei Basso De Caro ML, et al. Expression and function of somatostatin receptor subtype l in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004; 79(3): 142-8.
42. Gillespie TJ, Erenberg A, Kim S, Dong J, Taylor JE, Hau V, et al. Novel somatostatin analogs for the treatment of acromegaly and cancer exhibit improved in vivo stability and distribution. J Pharmacol Exp Ther 1998; 285(1): 95-104.
43. Saveanu A, Gunz G, Dufour H, Caron P, Fina F, Ouafik L, et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J Clin Endocrinol Metab 2001; 86(1): 140-5.
44. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, et al. Demonstration of enhanced potency of a chimeric somatostatindopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J Clin Endoerinol Metab 2002; 87(12): 5545-52.
45. Nunn C, Rueping M, Langenegger D, Schuepbach E, Kimmcrlin T, Micuch P, et al beta(2)/beta(3)-di- and alpha/beta(3)-tetrapeptide derivatives as potent agonists at somatostatin sst(4) receptors. Naunyn Schmiedebergs Arch Pharmacol 2003; 367(2): 95-103.
46. Lewis I, Bauer W, Albert R, Chandramouli N, Pless J, Weckbecker G, et al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem 2003; 46(12): 2334-44.
47. Reubi JC, Schaer JC, Wenger S, Hoeger C, Erchegyi J, Waser B, et al. SST3-selective potent peptidic somatostatin receptor antagonists. Proc Natl Acad Sei USA 2000; 97(25): 13973-8.
48. Erchegyi J, Waser B, Schaer JC, Cescato R, Brazeau JF, Rivier J, et al. Novel sst(4)-Selective Somatostatin (SRIF) Agonists. 3. Analogues Amenable to Radiolabeling. J Med Chem 2003; 46(26): 5597-56051.
49. Seebach D, Schaeffer L, Brenner M, Hoyer D. Design and synthesis of gamma-dipeptide derivatives with submicromolar affinities for human somatostatin receptors. Angew Chem Int Ed Engl 2003; 42(7): 776-8.
50. Weckbecker G, Briner U, Lewis I, Bruns C. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates. and dogs. Endocrinology 2002; 143(10): 4123-30.
51. Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002; 146(5): 707-16.
52. Afargan M, Janson ET, Gelerman G, Roscnfeld R, Ziv O, Karpov O, et al. Novel long-acting somatostatin analog with endocrine selectivity: potent suppression of growth hormone but not of insulin. Endocrinology 2001; 142(1): 477-86.
53. Reubi JC, Eisenwiener KP, Rink H, Waser B, Macke HR. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. Eur J Pharmacol 2002; 456(1-3): 45-9.
54. Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science 1998; 282(5389): 737-40.
55. Yang L, Guo L, Pasternak A, Mosley R, Rohrer S, Birzin E, et al. Spiro[1H-indene-1, 4′-piperidine] derivatives as potent and selective non-peptide human somatostatin receptor subtype 2 (sst2) agonists. J Med Chem 1998; 41(13): 2175-9.
56. Pasternak A, Pan Y, Marino D, Sanderson PE, Mosley R, Rohrer SP, et al. Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg Med Chem Lett 1999; 9(3): 491-6.
57. Tulipano G, Soldi D, Bagnasco M, Culler MD, Taylor JE, Cocchi D, et al. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 2002; 143(4): 1218-24.
58. Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, et al. Identification and characterization of novel somatostatin antagonists. Mol Pharmacol 1996; 50(4): 709-15.
59. Feniuk W, Jarvie E, Luo J, Humphrey PP. Selective somatostatin sst(2) receptor blockade with the novel cyclic octapeptide, CYN-154806. Neuropharmacology 2000; 39(8): 1443-50.
60. Nunn C, Schoeffter P, Langenegger D, Hoyer D. Functional characterisation of the putative somatostatin sst2 receptor antagonist CYN 154806. Naunyn Schmiedebergs Arch Pharmacol 2003; 367(1): 1-9.
61. Nunn C, Langenegger D, Hurth K, Schmidt K, Fehhnann D, Hoyer D. Agonist properties of putative small-molecule somatostatin sst(2) receptor-selective antagonists. Eur J Pharmacol 2003; 465(3): 211-8.
62. Hoyer D, Dixon K, Gentsch C, Vassout A, Enz A, Jaton A, et al. NVP-SRA880, a somatostatin sstl receptor antagonist promotes social interactions, reduces aggressive behaviour and stimulates learning. The pharmaeologist 2002; 44(suppl. 1): A254.
63. Poitout L, Roubert P, Contour-Galcera MO, Moinet C, Lannoy J, Pommier J, et al. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. J Med Chem 2001; 44(18): 2990-3000.
64. Lamberts SW, Uitterliinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Erigi J Med 1985; 313(25): 1576-80.
65. Lamberts SW, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 1985; 60(6): 1161-5.
66. Burt M, Ho K. Comparison of efficacy and tolerability of somatostatin analogs and other therapies for acromegaly. Endocrine 2003; 20(3): 299-306.
67. Danoff A, Kleinberg D. Somatostatin analogs as primary medical therapy for acromegaly. Endocrine 2003; 20(3): 291-8.
68. Saveanu A, Morange-Ramos I, Gunz G, Dufour H, Enjalbert A, Jaquet P. A luteinizing hormone-, alpha-subunit- and prolactin-secreting pituitary adenoma responsive to somatostatin analogs: in vivo and in vitro studies. Eur J Endocrinol 2001; 145(1): 35-41.
69. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003; 148(4): 433-42.
70. Colao A, Filippella M, Somma C, Manzi S, Rota F, Pivonello R, et al. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine 2003; 20(3): 279-84.
71. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, et al. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 1999; 84(9): 3268-76.
72. Lamberts SW, de Herder WW, Hofiand LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002; 13(10): 451-7.
73. De Herder W, Lamberts S. Somatostatin analog therapy in treatment of gastrointestinal disorders and tumors. Endocrine 2003; 20(3): 285-90.
74. Ren SG, Taylor J, Dong J, Yu R, Culler MD, Melmed S. Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab 2003; 88(9): 4239-45.
75. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin/dopaminergic chimeric ligand. J Clin Endocrinol Metab 2003; 88(11): 5414-21.
76. van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004; 89(2): 638-45.
77. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 2004; 89(4): 1577-85.
78. Cervia D, Nunn C, Fehlmann D, Langenegger D, Schuepbach E, Hoyer D. Pharmacological characterisation of native somatostatin receptors in AtT-20 mouse tumour corticotrophs. Br J Pharmacol 2003; 139(1): 109-21.
79. Cervia D, Fehlmann D, Hoyer D. Native somatostatin sst2 and sst5 receptors functionally coupled to G(i/o)-protein, but not to the serum response element in AtT-20 mouse tumour corticotrophs. Naunyn Schmiedebergs Arch Pharmacol 2003; 367(6): 578-87.
80. Bousquet C, Puente E, Buscail L, Vaysse N, Susini C. Antiproliferative effect of somatostatin and analogs. Chemotherapy 2001; 47(Suppl 2): 30-9.
81. Scarpignato C, Pelosini I. Somatostatin analogs for cancer treatment and diagnosis: an overview. Chemotherapy 2001; 47(Suppl 2): 1-29.
82. Lahlou H, Saint-Laurent N, Esteve JP, Eychene A, Pradayrol L, Pyronnet S, et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 2003; 278(41): 39356-71.
83. Garcia de la Torre N, Wass JA, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf) 2002; 57(4): 425-41.
84. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003; 144(4): 1574-84.
85. Dalm VA, van Hagen PM, van Koetsveld PM, Achilefu S, Houtsmuller AB, Pois DH, et al. Expression of somatostatin, cortistatin, and somatostatin receptors in human monocytes, macrophages, and dendritic cells. Am J Physiol Endocrinol Metab 2003; 285(2): E344-53.
86. Dalm VA, van Hagen PM, van Koetsveld PM, Langerak AW, van der Lely AJ, Lamberts SW, et al. Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system. J Clin Endocrinol Metab 2003; 88(1): 270-6.
87. Ferone D, Pivonello R, Van Hagen PM, Dalm VA, Lichtenauer-Kaligis EG, Waaijers M, et al. Quantitative and functional expression of somatostatin receptor subtypes in human thymocytes. Am J Physiol Endocrinol Metab 2002; 283(5): E 1056-66.
88. Raderer M, Hejna MH, Muller C, Kornek GV, Kurtaran A, Virgolini I, et al. Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo. Int J Oncol 2000; 16(6): 1197-201.
89. Gonzalez-Barcena D, Schally AV, Vadillo-Buenfil M, Cortez-Morales A, Hemandez LV, Cardenas-Comejo I, et al. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the rime of relapse. Prostate 2003; 56(3): 183-91.
90. O'Byrne KJ, Dobbs N, Propper DJ, Braybrooke JP, Koukourakis MI, Mitchell K, et al. Phase II study of RC-160 (vapreotide), an octapeptide analogue of somatostatin, in the treatment of metastatic breast cancer. Br J Cancer 1999; 79(9-10): 1413-8.
91. Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002; 36(3): 687-91.
92. Hejna M, Schmidinger M, Raderer M. The clinical role of somatostatin analogues as antineoplastic agents: much ado about nothing? Ann Oncol 2002; 13(5): 653-68.
93. Stirnweiss J, Hartrodt B, Greksch G, Sturzebecher U, Bohmer FD, Neubert K, et al. Tyr-c[D-Om-Tyr(Bzl)-Pro-Gly]: a novel antiproliferative acting somatostatin receptor agonist with muopioid receptor-sensitizing properties. Br J Pharmacol 2003; 140(1): 13-22.
94. Kampa M, Bakogeorgou E, Hatzoglou A, Damianaki A, Martin PM, Castanas E. Opioid alkaloids and casomorphin peptides decrease the proliferation of prostatic cancer cell lines (LNCaP, PC3 and DU145) through a partial interaction with opioid receptors. Eur J Pharmacol 1997; 335(2-3): 255-65.
95. Virgolini I, Traub T, Novotny C, Leimer M, Fuger B, Li SR, et al. Experience with indium-111 and yttrium-90-1abeled somatostatin analogs. Curr Pharm Des 2002; 8(20): 1781-807.
96. Slooter GD, Mearadji A, Breeman WA, Marquet RL, de Jong M, Krenning EP, et al. Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours. Br J Surg 2001; 88(1): 3140.
97. Hofland LJ, Lamberts SW, van Hagen PM, Reubi JC, Schaeffer J, Waaijers M, et al. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phel]octreotide in somatostatin receptor-positive organs. J Nucl Med 2003; 44(8): 1315-21.
98. Capello A, Krenning EP, Breeman WA, Bernard BF, de Jong M. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0] octreotide. J Nucl Med 2003; 44(1): 98-104.
99. Breeman WA, de Jong M, Kwekkeboom DJ, Valkema R, Bakker WH, Kooij PP, et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives. Eur J Nucl Med 2001; 28(9): 1421-9.
100. Breeman WA, De Jong M, Visser TJ, Erion JL, Krenning EP. Optimising conditions for radiolabelling of DOTA-peptides with 90Y, 111In and 177Lu at high specific activities. Eur J Nucl Med Mol Imaging 2003; 30(6): 917-20.
101. Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-1abelled somatostatin-analogue for cancer treatment. Lancet 1998; 351(9100): 417-8.
102. Bushnell D, O'Dorisio T, Menda Y, Carlisle T, Zehr P, Connolly M, et al. Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors. J Nucl Med 2003; 44(10): 1556-60.
103. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000; 27(3): 273-82.
104. de Jong M, Breeman WA, Bemard BF, Bakker WH, Schaar M, van Gameren A, et al. [177Lu-DOTA(0), Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy. Int J Cancer 2001; 92(5): 628-33.
105. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001; 28(9): 1319-25.
106. Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, De Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [(177)Lu-DOTA(0), Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2003; 30(3): 417-22.
107. De Jong M, Valkema R, Jamar F, Kvols LK, Kwekkeboom DJ, Breeman WA, et al. Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med 2002; 32(2): 133-40.
108. de Jong M, Breeman WA, Bernard BF, Bakker WH, Visser TJ, Kooij PP, et al. Tumor response after [(90)Y-DOTA(0), Tyr(3)] octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med 2001; 42(12): 1841-6.
109. Lewis JS, Lewis MR, Cutler PD, Srinivasan A, Schmidt MA, Schwarz SW, et al. Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. Clin Cancer Res 1999; 5(11): 3608-16.
110. Wang M, Caruano AL, Lewis MR, Meyer LA, VanderWaal RP, Anderson CJ. Subcellular localization of radiolabeled somatostatin analogues: implications for targeted radiotherapy of cancer. Cancer Res 2003; 63(20): 6864-9.
111. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci 2003; 72(21): 2305-20.
112. Nagy A, Schally AV, Halmos G, Armatis P, Cai RZ, Csemus V, et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc Natl Acad Sci USA 1998; 95(4): 1794-9.
113. Magrath IT. Targeted approaches to cancer therapy. Int J Cancer 1994; 56(2): 163-6.
114. Letsch M, Schally AV, Szepeshazi K, Halmos G, Nagy A. Effective Treatment of Experimental Androgen Sensitive and Androgen Independent Intraosseous Prostate Cancer With Targeted Cytotoxic Somatostatin Analogue AN-238. J Urol 2004; 171(2): 911-915.
115. Szepeshazi K, Schally AV, Nagy A, Wagner BW, Bajo AM, Halmos G. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas. Cancer 2003; 98(7); 1401-10.
116. Flogstad AK, Halse J, Haldorsen T, Lancranjan I, Marbach P, Bruns C, et al. Sandostatin LAR in acromegalic patients: a dose-range study. J Clin Endocrinol Metab 1995; 80( 12): 3601-7.
117. Grass P, Marbach P, Bruns C, Lancranjan I. Sandostatin LAR (microencapsulated octreotide acetate) in acromegaly: pharmacokinetic and pharmacodynamic relationships. Metabolism 1996; 45(8 Suppl 1): 27-30.
118. Clemmons DR, Chihara K, Freda PU, Ho KK, Klibanski A, Melmed S, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003; 88(10): 4759-67.
119. Mitra SW, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, et al. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. Endocrinology 1999; 140(8): 3790-6.
120. Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, et al. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. Mol Endocrinol 2003; 17(1): 93-106.
121. Brunicardi FC, Atiya A, Moldovan S, Lee TC, Fagan SP, Kleinman RM, et al. Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. Pancreas 2003; 27(4): E84-9.
122. Watdherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of 90Y-DOTA-D-Phel-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12(7): 941-5.
123. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999; 26(11): 1439-47.
124. Otte A, Cybulla M, Weiner SM. 90Y-DOTATOC and nephrotoxicity. Eur J Nucl Med Mol Imaging 2002; 29(II): 1543.
125. Smith MC, Liu J, Chen T, Schran H, Yeh CM, Jamar F, et al. OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy. Digestion 2000; 62 Suppl 1: 69-72.
126. Hammond PJ, Wade AF, Gwilliam ME, Peters AM, Myers MJ, Gilbey SG, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue. Br J Cancer 1993; 67(6): 1437-9.